RESEARCH PAPER

Precision Pharmacological Stratification and Targeted Management of Pathological Menopause: Evidence-Based Hormone Replacement Therapy Optimization, Non-Hormonal Pharmacotherapy, and Personalized Strategies in Premature Ovarian Insufficiency and Iatrogenic Forms

Marg'uba Rasulova[1], Gulliyeva Nozima Shavkatovna[2], Khakimova Zulkhumor Karimovna[3], Mohira Mahmud qizi Toshtemirova[4], Khakimov Valikhan Alikhanovich[5], Xurshida Pulatovna Kenjayeva[6]

[1] D.M.Sc. Professor of Ecology, Obstetrics, Gynecology, National University of Uzbekistan after Mirzo Ulugbek, Street University 4, 100174, Tashkent, Uzbekistan. Email: rasulovamarguba230@gmail.com | ORCID: https://orcid.org/0009-0003-7086-0268

[2] Trainee Lecturer, Turon University, 1/14 Nasaf Street, 180111, Karshi, Kashkadarya Region, Uzbekistan. Email: Gulliyevanozima5@gmail.com | ORCID: https://orcid.org/0009-0003-7198-3550

[3] Associate Professor, Department of Ophthalmology, Center for the Development of Professional Qualifications of Medical Workers, 51 Parkent Street, 100007, Tashkent, Uzbekistan. Email: hzk-kaf@umail.uz | ORCID: https://orcid.org/0000-0002-7428-8882

[4] Assistant, Department of Therapeutic Dentistry, Samarkand State Medical Institute, Street Amir Temur, 18A, 140100, Samarkand, Uzbekistan. Email: mohitoshtemirova1998@gmail.com | ORCID: https://orcid.org/0009-0003-4471-7257

[5] Associate Professor, Department of Public Health and Healthcare Management, Center for the Development of Professional Qualifications of Medical Workers, 51 Parkent Street, 100007, Tashkent, Uzbekistan. Email: hva-kaf1@umail.uz | ORCID: https://orcid.org/0000-0003-3236-0046

[6] Department of Social Sciences, Bukhara State Medical Institute, Street Gijduvan 23, 200126, Bukhara, Uzbekistan. Email: kenjayeva.xurshida@bsmi.uz | ORCID: https://orcid.org/0009-0001-5648-1822

Received: 15th Feb, 2026; **Revised:** 27th Feb, 2026; **Accepted:** 20th Mar, 2026; **Available Online:** 5th Apr, 2026

ABSTRACT

Background

Pathological menopause, which encompasses premature ovarian insufficiency (POI), early menopause, and iatrogenically induced variants, represents a critical and often devastating deviation from the normative reproductive aging trajectory. Affecting approximately 3.5% to 5% of women globally, it precipitates an abrupt and profound cessation of ovarian endocrine function. This early-onset hypoestrogenism subjects affected individuals to severe vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), and exponentially accelerates the longitudinal risk of cardiovascular disease, osteoporosis, and neurocognitive decline.

Methods

This comprehensive systematic review synthesizes high-impact evidence from recent international clinical guidelines spanning 2024 to 2026, including comprehensive frameworks from the European Society of Endocrinology (ESE), the American Society for Reproductive Medicine (ASRM), and the International Menopause Society (IMS). A systematic analysis of phase 3 clinical trials, pharmacogenomic studies, artificial intelligence-driven predictive models, and regenerative medicine research was conducted to outline precision management algorithms for highly stratified patient cohorts.

Results

The optimization of menopausal hormone therapy (MHT) relies heavily on pharmacological risk stratification, emphasizing the shift toward transdermal 17β-estradiol combined with micronized progesterone to mitigate venous thromboembolism (VTE) and oncological risks. Estetrol (E4), a native fetal estrogen with selective tissue activity, emerges as a highly favorable alternative demonstrating neutral cardiovascular and hemostatic profiles in the recent E4COMFORT phase 3 trials. For patients with absolute contraindications to MHT, particularly breast cancer survivors experiencing iatrogenic menopause, the approval of neurokinin-3 (NK3) receptor antagonists (fezolinetant and elinzanetant) represents a paradigm shift in mitigating VMS via direct hypothalamic modulation without systemic

endocrine effects. Furthermore, the integration of pharmacogenomic testing (e.g., CYP2D6, ESR1) and artificial intelligence-driven predictive models significantly enhances therapeutic individualization. Regenerative frontiers, particularly hypoxic mesenchymal stem cell-derived exosomes acting via the SIRT3/PGC-1α pathway, offer unprecedented potential for ovarian follicle rescue and functional restoration.

Conclusion

The contemporary management of pathological menopause necessitates an immediate departure from standardized, empirical protocols in favor of precision, biomarker-guided stratification. By synthesizing advanced pharmacotherapy, non-hormonal innovations, and resolving profound global health equity gaps, this multidisciplinary approach ensures optimized long-term health span and quality of life for women experiencing premature estrogen deprivation.

Keywords: premature ovarian insufficiency; pathological menopause; menopausal hormone therapy; neurokinin-3 receptor antagonists; vasomotor symptoms; pharmacogenomics; precision medicine; regenerative ovarian therapy

How to cite this article: Rasulova M, Shavkatovna GN, Karimovna KZ, Toshtemirova MM, Alikhanovich KV, Kenjayeva XP. Precision Pharmacological Stratification and Targeted Management of Pathological Menopause: Evidence-Based Hormone Replacement Therapy Optimization, Non-Hormonal Pharmacotherapy, and Personalized Strategies in Premature Ovarian Insufficiency and Iatrogenic Forms. Int J Drug Deliv Technol. 2026;16(25s): 77-89. DOI: 10.25258/ijddt.16.25s.8

Source of support: Nil.

Conflict of interest: None

Introduction and the STRAW+10 Framework

Menopause constitutes a universal and biologically inevitable transition in a woman's reproductive trajectory. It is fundamentally defined as the permanent cessation of menstrual cycles resulting from the physiological depletion of the ovarian primordial follicle reserve. In normative, healthy populations, this transition occurs at a median age of 51 years and is orchestrated by a highly complex interplay of genetic heritability (with twin studies demonstrating heritability estimates between 44% and 53%), environmental exposures, nutritional status, reproductive history, and lifelong lifestyle determinants [25]. The STRAW+10 (Stages of Reproductive Aging Workshop +10) framework provides the international gold-standard nomenclature for this physiological aging process. It delineates seven distinct stages from the reproductive prime through the late postmenopause, utilizing menstrual cycle variability, elevated follicle-stimulating hormone (FSH) levels, and declining anti-Müllerian hormone (AMH) concentrations to accurately stage reproductive senescence [39].

However, pathological menopause represents a clinically severe disruption of this biological timeline, triggering an abrupt endocrine collapse decades before the physiological norm [55]. This umbrella term encompasses three primary clinical entities that require highly specialized, precision-guided management:

1. **Premature Ovarian Insufficiency (POI):** Defined as the pathological loss of ovarian activity before the age of 40 years.
2. **Early Menopause:** The cessation of ovarian function occurring abnormally early, strictly defined between the ages of 40 and 44 years.
3. **Iatrogenic Menopause:** Induced abruptly at any age via surgical interventions (such as bilateral salpingo-oophorectomy), severe pelvic radiotherapy, or the administration of gonadotoxic chemotherapy regimens (e.g., alkylating agents used in oncology).

The abrupt loss of systemic estrogen in these cohorts is profoundly destabilizing. Clinically, up to 80% of affected women experience severe vasomotor symptoms (VMS), reporting multiple intense hot flash episodes daily, alongside a 50% incidence of genitourinary syndrome of menopause (GSM), which is characterized by vaginal atrophy, dyspareunia, and recurrent, debilitating urinary tract infections [46]. Beyond acute symptomatology, the systemic sequelae of prolonged, untreated hypoestrogenism are devastating. Women experiencing pathological menopause face a 50% to 100% increased relative risk of cardiovascular disease (CVD) and ischemic stroke, an accelerated rate of osteoclast-mediated bone resorption leading to a doubled risk of fragility fractures, and significant neurocognitive impairments [55]. Recent longitudinal imaging studies link early estrogen deprivation to reduced hippocampal volume, accelerated amyloid- deposition, and a significantly elevated hazard ratio for early-onset dementia [47]. The European Society of Endocrinology (ESE) Clinical Practice Guideline, updated extensively in late 2025, explicitly mandates that the clinical management of POI and early menopause must be approached differently than normative middle-aged

menopause, necessitating specialized, multidisciplinary care models and precision pharmacological dosing [33].

Epidemiology and Global Health Equity Gaps

Recent meta-analyses and global registries spanning 2024 to 2026 indicate that the global prevalence of POI and early menopause combined reaches 3.5% to 3.7%, a figure notably higher than historical estimates of 1% [37]. This prevalence is not distributed equally across demographic lines. Certain populations, such as African-American and Hispanic cohorts, bear a disproportionately higher burden of early-onset symptoms and POI, with prevalence rates reaching up to 3.5% in these specific groups alone.

A critical dimension of modern menopause management is the recognition of profound global health equity gaps. Research published in 2025 emphasizes that the benefits of recent pharmacological advancements and clinical awareness are not being felt equally across the globe, or even within high-income nations. For instance, the MenopauseGAP study revealed that Black and Asian women in the UK are approximately 80% less likely to receive prescriptions for hormone replacement therapy (HRT) compared to their Caucasian counterparts [42]. These inequalities are deeply shaped by intersecting factors of ethnicity, socioeconomic status, and varying cultural norms regarding female aging and symptom reporting.

In low- and middle-income countries (LMICs), the incidence of POI is often exacerbated by untreated infectious diseases, severe malnutrition, and a lack of access to basic diagnostic endocrinology. Furthermore, symptoms among women of color are frequently normalized or dismissed by healthcare providers, leading to dangerous delays in diagnosis and the initiation of bone-protecting and cardioprotective therapies. Closing this equity gap requires the implementation of culturally adapted community interventions, the diversification of clinical trial populations (which currently suffer from persistent underrepresentation of ethnic minorities), and the widespread distribution of validated, accessible screening tools like the Menopause Quick 6 (MQ6) in primary care settings globally [28].

Etiological Architecture and Molecular Pathogenesis

The etiology of pathological menopause is highly heterogeneous and complex. Historically, up to 80% of POI cases were classified as "idiopathic." However, the integration of next-generation sequencing (NGS), whole-exome sequencing, and comprehensive autoimmune profiling into standard clinical practice has drastically reduced this proportion, uncovering precise molecular drivers and allowing for targeted therapeutic interventions [46].

Genetic Aberrations and Transcriptional Disruptions

Genetic anomalies represent the leading identified cause of non-iatrogenic POI, accounting for 20% to 30% of all familial cases. The premutation of the *FMR1* (fragile X mental retardation 1) gene is the most prevalent monogenic etiology. Women carrying 55 to 200 CGG trinucleotide repeats in the 5' untranslated region of the *FMR1* gene experience a profound RNA toxicity mechanism. Unlike full fragile X syndrome (which results from a lack of the FMRP protein), premutation carriers produce significantly elevated levels of *FMR1* mRNA (4 to 8 times higher than normal levels). This toxic mRNA sequesters critical RNA-binding proteins, leading to widespread cellular dysfunction, mitochondrial stress, and exponentially accelerated follicular atresia.

Chromosomal abnormalities, notably Turner syndrome (45,X) and its myriad mosaic variants (e.g., 45,X/46,XX), account for 10% to 15% of POI cases diagnosed in women under the age of 30. This condition is driven by the haploinsufficiency of critical ovarian-determining genes on the X chromosome, leading to the formation of dysgenetic streak gonads and the rapid, massive depletion of oocytes during fetal development or early childhood. Furthermore, NGS panels and genome-wide association studies (GWAS) have identified over 100 polygenic loci implicated in POI. Key mutations include disruptions in the transcription factor *FOXL2* (which causes blepharophimosis-ptosis-epicanthus inversus syndrome type I), as well as defects in oocyte-secreted factors like *BMP15* and *GDF9*. These factors are strictly required for the critical developmental transition from primary to secondary ovarian follicles; their absence results in absolute follicular arrest [46].

Autoimmune Pathology

Autoimmune oophoritis is responsible for 10% to 20% of pathological menopause cases. Pathologically, it is characterized by highly specific lymphocytic infiltration targeting the theca-interstitial cells of the ovary (leaving the granulosa cells and oocytes largely unaffected), which severely disrupts steroidogenesis and estrogen production. Ovarian autoimmunity is rarely an isolated phenomenon; it exhibits a high clinical overlap with autoimmune thyroiditis (Hashimoto's disease). Thyroid peroxidase (TPO) antibodies are detected in 14% to 27% of POI patients, necessitating routine thyroid surveillance.

In its most severe manifestation, POI occurs in up to 60% of females with Autoimmune Polyglandular Syndrome Type 1 (APS-1). This devastating autosomal

recessive disorder is caused by mutations in the *AIRE* gene, which regulates the expression of tissue-specific antigens in the thymus. A defective *AIRE* gene results in the failure of negative selection for self-reactive T-cells, leading to a profound loss of central immune tolerance. Patients with APS-1 frequently harbor antibodies against 21-hydroxylase, placing them at severe risk for sudden adrenal crisis, which must be managed concurrently with their POI [1-46].

Iatrogenic and Environmental Drivers

Iatrogenic menopause is predominantly secondary to aggressive oncological treatments and prophylactic surgeries. Alkylating chemotherapeutic agents, such as cyclophosphamide, induce direct double-strand DNA crosslinking, triggering massive apoptotic cascades in granulosa cells and primordial oocytes. Young breast cancer survivors subjected to multi-agent chemotherapy face a POI risk ranging from 40% to 80%, which is highly dependent on the cumulative chemotherapeutic dose and the patient's age at exposure. Pelvic radiotherapy demonstrates a strict, irreversible dose-response relationship; exposures exceeding 6 Gray to the ovarian field cause permanent catastrophic failure in 90% of cases [55].

Simultaneously, environmental endocrine disruptors—such as bisphenol A (BPA), phthalates, and polycyclic aromatic hydrocarbons (PAHs) found in tobacco smoke—exert toxic effects via the activation of the aryl hydrocarbon receptor. This activation dramatically increases oxidative stress and lipid peroxidation within the ovarian microenvironment, advancing the age of menopause by an average of 1.5 to 2 years and conferring an odds ratio (OR) of 1.5 for early follicular depletion [45].

Table 1

Etiological Categories, Pathogenic Mechanisms, Diagnostic Biomarkers, and Molecular Determinants of Premature Ovarian Insufficiency

Etiology Category	Prevalence	Primary Pathogenic Mechanism	Diagnostic Biomarkers	Genetic/Molecular Basis
Genetic (FMR1)	20-30% familial	RNA toxicity via elevated mRNA	FMR1 PCR, Southern blot	CGG repeat expansion (55-200)
Genetic (Chromosomal)	10-15% (<30 yrs)	Accelerated atresia, streak gonads	Karyotype, Array CGH	X-chromosome haploinsufficiency
Autoimmune (Thyroid)	14-27% overlap	Lymphocytic theca cell infiltration	TPO/TG antibodies, TSH	CTLA4, PTPN22 risk alleles
Autoimmune (APS-1)	0.5-2% of POI	Defective thymic T-cell selection	AIRE sequencing, 21-OH Abs	AIRE (21q22.3) recessive mutation
Iatrogenic (Chemo)	40-80% young oncology	DNA crosslinking, massive apoptosis	Pre/post-treatment AMH and FSH	Mitochondrial oxidative stress
Environmental	Variable	Aryl hydrocarbon receptor activation	Cotinine, Urine BPA metabolites	Impaired steroidogenesis

Advanced Diagnostic Paradigms

The diagnostic criteria for pathological menopause have undergone significant refinement in the 2024 and 2025 guidelines published by ESHRE, ASRM, and the IMS. Historically, women suffered from prolonged diagnostic delays, often enduring symptoms for over two years before receiving a definitive diagnosis. The traditional reliance on prolonged periods of absolute amenorrhea has been superseded by more aggressive and proactive diagnostic algorithms.

The current clinical standard strictly requires the presence of oligomenorrhea (fewer than 9 menstrual periods per year) or amenorrhea for at least four months in a woman under the age of 40, coupled with profoundly elevated serum follicle-stimulating hormone (FSH) [55]. The 2024 ESHRE updates stipulate that while historically two FSH measurements were required, a single measurement of highly elevated FSH (>25 IU/L) may now be sufficient for diagnosis in clear clinical contexts, though

repeat testing or AMH measurement is strongly advised when diagnostic uncertainty persists [32].

The integration of Anti-Müllerian hormone (AMH) into the diagnostic paradigm represents a crucial advancement. AMH is secreted exclusively by preantral and small antral follicles and serves as a highly sensitive, cycle-independent biomarker of the true residual ovarian reserve. An AMH concentration of <1.0 ng/mL strongly correlates with absolute follicular depletion and is indispensable in confirming POI, particularly in cases where residual, intermittent ovarian activity temporarily normalizes FSH levels [46]. Indeed, ovarian function in POI is notoriously unpredictable; intermittent ovulation occurs in 50% to 75% of non-iatrogenic cases, resulting in spontaneous pregnancies in 4% to 8% of women post-diagnosis. This clinical reality necessitates rigorous contraceptive counseling for patients who do not desire pregnancy, while managing the complex psychological expectations of those seeking fertility preservation [11].

In primary care settings, the implementation of the Menopause Quick 6 (MQ6) tool has vastly improved the identification of menopausal transitions. The MQ6 systematically screens for menstrual changes, VMS, vaginal dryness/dyspareunia, bladder issues, sleep difficulties, and mood alterations, facilitating rapid triage and minimizing the window of untreated hypoestrogenism [28].

Precision Pharmacological Stratification Algorithm

The empirical, generalized application of Menopausal Hormone Therapy (MHT) is obsolete in the era of precision medicine [56]. Based on robust, large-scale longitudinal data—most notably the 20-year extended follow-up analyses of the Women's Health Initiative (WHI) trials published between 2024 and 2025—the initiation of MHT must be strictly guided by individual baseline cardiovascular, metabolic, and oncological risk stratification [54]. The fundamental principle guiding this approach is the "timing hypothesis": MHT confers maximal cardioprotective and osteo-protective benefits, significantly reducing all-cause mortality, only when initiated in women under 60 years of age or within 10 years of the onset of menopause [21].

According to the 2025 European Society of Endocrinology (ESE) guidelines, patients must be algorithmically sorted into specific risk tiers to determine the safety, route, and composition of pharmacological intervention [33].

The Stratification Tiers

1. **Low Risk Tier:** Women under age 60, within 10 years of their final menstrual period, with a Body Mass Index (BMI) <30 kg/m^2, normotensive, non-smokers, and lacking any personal history of cardiovascular disease (CVD) or venous thromboembolism (VTE). These individuals are optimal candidates for early, standard MHT (either oral or transdermal) to mitigate symptoms and prevent long-term skeletal degradation.

2. **Intermediate Risk Tier:** Women presenting with mild metabolic syndrome, a family history of severe CVD, former smokers, or those with controlled hypertension. In this cohort, oral estrogens must be avoided due to the hepatic first-pass effect, which upregulates coagulation factors and angiotensinogen. Precision management mandates the strict use of transdermal 17β-estradiol (patches or gels), which completely bypasses liver metabolism, maintaining a neutral risk profile for VTE and stroke.

3. **High Risk Tier:** Women with a history of hormone-dependent malignancies (e.g., ER+ breast cancer), prior unprovoked VTE, advanced uncontrolled CVD, or active liver disease.[8] For these patients, systemic MHT is absolutely contraindicated. Treatment must pivot entirely to targeted non-hormonal pharmacotherapies (such as NK3 receptor antagonists) for VMS, and localized, ultra-low-dose treatments for genitourinary symptoms.

Optimization of Menopausal Hormone Therapy (MHT)

For patients in the low to intermediate risk tiers, and universally for patients with POI lacking specific contraindications, MHT remains the undisputed gold standard. Optimized regimens provide a 70% to 90% reduction in VMS severity and frequency, and a 50% to 55% reduction in the relative risk of osteoporotic fragility fractures [25].

The choice of progestogen is just as critical as the estrogen route. In women with an intact uterus, estrogen monotherapy invariably induces potentially fatal endometrial hyperplasia and adenocarcinoma. While synthetic progestins like medroxyprogesterone acetate (MPA) were historically linked to slight increases in breast cancer risk during the WHI trials, modern precision protocols strongly advocate for the use of bioidentical micronized progesterone or highly selective dydrogesterone. These modern agents provide robust endometrial protection while remaining metabolically neutral—they do not negate the cardiovascular benefits of estrogen, do not alter lipid profiles unfavorably, and carry a significantly lower risk profile for breast cell proliferation compared to older synthetic derivatives. Recognizing the safety of optimized regimens, the FDA officially removed the severe "boxed warnings" from appropriately prescribed

MHT products in late 2025, affirming their safety for symptom relief in indicated populations [53].

The Emergence of Estetrol (E4)

A revolutionary development in estrogen pharmacology is the clinical integration of Estetrol (E4). E4 is a native fetal estrogen, synthesized exclusively by the human fetal liver during pregnancy, featuring a highly unique mechanism of action known as NEST (Native Estrogen with Selective Tissue activity).[11] E4 acts as a robust agonist in the central nervous system, bone tissue, and vaginal epithelium, effectively eliminating VMS and preserving bone mass. Concurrently, it acts as an antagonist or exhibits negligible activity in breast tissue and the liver.

The landmark E4COMFORT phase 3 clinical trials (2024-2025) rigorously evaluated oral E4 at 15 mg and 20 mg dosages for the treatment of moderate-to-severe VMS,. The results demonstrated highly significant, rapid reductions in VMS frequency. By week 12, the 100% responder rates (complete cessation of hot flashes) reached 32.5% for the 15 mg dose and 38.5% for the 20 mg dose, compared to just 17.4% for placebo. Crucially, the E4COMFORT II trial confirmed that 52 weeks of continuous E4 therapy had absolutely no detrimental impact on systemic blood pressure, even in high-risk postmenopausal women presenting with baseline metabolic risk factors such as elevated HbA1c (pre-diabetes), elevated triglycerides, and low HDL cholesterol. Because it exerts negligible effects on hemostasis and liver globulins, Estetrol is positioned to become the premier oral estrogen alternative, maximizing therapeutic efficacy while virtually eliminating the cardiovascular and thrombotic risks associated with traditional oral estrogens [22].

Targeted Management of Premature Ovarian Insufficiency (POI)

The pharmacological strategy for managing POI diverges fundamentally from that of natural, middle-aged menopause. Because women with POI face severe estrogen deprivation decades prematurely, their therapeutic requirements are substantially higher to effectively mimic the physiological premenopausal endocrine environment.

The 2024 and 2025 guidelines from ESHRE, ASRM, and the IMS strictly mandate the immediate initiation of MHT upon the diagnosis of POI.[4] Therapy must be continued continuously at least until the average age of natural menopause (approximately 51 years).[4] Standard menopausal estrogen doses (e.g., 1 mg oral estradiol or 50 micrograms transdermal) are demonstrably inadequate for POI patients. Precision dosing requires significantly higher regimens—such as 2 mg of oral estradiol or 100 micrograms of transdermal estradiol daily—to ensure optimal bone mineral density (BMD) accrual, suppress hypergonadotropic symptoms, and provide comprehensive cardiovascular protection.

Adherence to high-dose MHT in the POI cohort is not merely for symptom relief; it is a life-saving intervention. Longitudinal cohort data explicitly demonstrate that POI patients who adhere to these high-dose regimens have drastically reduced hazard ratios for ischemic stroke, severe osteoporosis, and early-onset dementia compared to non-users or those with delayed initiation (delaying treatment beyond 5 years post-diagnosis). Despite these proven benefits, 2026 data indicate a concerning reality: widespread misinformation and unwarranted fears regarding cancer risks lead to massive underutilization of MHT in women with POI, highlighting an urgent need for targeted patient education and specialized clinical pathways [32, 42, 55].

Iatrogenic Menopause and Oncology Survivorship

Iatrogenic menopause, particularly that induced by breast cancer treatments such as aromatase inhibitors (AIs) or tamoxifen, presents the highest level of complexity within the pharmacological stratification algorithm. Systemic MHT is universally contraindicated in patients with a history of hormone receptor-positive (ER+) malignancies due to the unacceptable risk of cancer recurrence.

The profound estrogen ablation induced by AIs (e.g., letrozole, anastrozole) drives estrogen levels to near zero. This chemical ablation frequently causes devastating VMS, rapid-onset genitourinary syndrome of menopause (GSM), and a uniquely debilitating condition known as AI-induced arthralgia. This severe joint pain and morning stiffness affects the hands, knees, and lower back in over 50% of treated women, significantly compromising quality of life and frequently leading to the premature discontinuation of life-saving cancer therapies [29].

For the management of severe GSM in this ultra-high-risk oncology cohort, non-hormonal vaginal moisturizers and lubricants must be optimized as first-line therapy. However, if vaginal atrophy and dyspareunia remain entirely refractory to non-hormonal measures, updated 2025 consensus statements from major oncological and urological societies support the highly cautious, shared-decision-making use of ultra-low-dose topical vaginal estrogens or intravaginal dehydroepiandrosterone (DHEA).[19] Pharmacokinetic studies confirm that these localized therapies undergo negligible systemic absorption, theoretically preserving

oncological safety while providing critical relief from severe mucosal atrophy [51].

Innovations in Non-Hormonal Pharmacotherapy: Neurokinin-3 Receptor Antagonists

For women relegated to the high-risk tiers where MHT is strictly contraindicated, or for those who actively refuse hormonal interventions, the landscape of non-hormonal pharmacotherapy has been completely revolutionized by the development of highly selective neurokinin-3 (NK3) receptor antagonists.

The core pathophysiology of vasomotor symptoms is deeply rooted in the hypothalamic thermoregulatory center. KNDy neurons (which co-express kisspeptin, neurokinin B, and dynorphin) located in the arcuate nucleus undergo massive hypertrophy in the absence of the negative feedback normally provided by systemic estrogen. This hypertrophy triggers unregulated, excessive neurokinin B signaling through the NK3 receptor to the preoptic area of the brain. This severely narrows the body's thermoregulatory set-point, provoking profound, inappropriate heat-dissipation responses that manifest clinically as debilitating hot flashes and night sweats [58].

Fezolinetant and Elinzanetant

Fezolinetant: Approved globally by regulatory agencies in 2023, fezolinetant (administered orally at 45 mg/day) acts as a highly selective, non-hormonal NK3 receptor antagonist. By physically blocking the binding of neurokinin B in the hypothalamus, it effectively "resets" the thermoregulatory center. Clinical meta-analyses from 2025 confirm that fezolinetant achieves a remarkable 50% to 65% reduction in both VMS frequency and severity, functioning as the first highly effective non-hormonal alternative that rivals the efficacy of estrogen therapy.

Elinzanetant: Approved in late 2025, elinzanetant represents the next generation of this therapeutic class, functioning as a dual antagonist of both the NK1 and NK3 receptors.[21] The comprehensive OASIS-3 phase 3 clinical trials rigorously evaluated 120 mg of elinzanetant administered daily over a 52-week period,. Beyond robust suppression of hot flashes (demonstrating a sustained mean difference of -1.6 episodes per day versus placebo), elinzanetant leverages its NK1 receptor antagonism to directly and significantly improve sleep architecture. In the OASIS-3 trial, elinzanetant reduced the PROMIS Sleep Disturbance T-score by over 10 points by week 12, profoundly improving sleep efficiency and overall menopause-specific quality of life.

Crucially, elinzanetant demonstrated an outstanding long-term safety profile. It was not associated with any hepatotoxic effects, endometrial hyperplasia, or negative alterations in bone mineral density. Treatment-emergent adverse events (TEAEs) were generally mild, with somnolence occurring in 5.1% of patients (compared to 1.3% on placebo) and mild gastrointestinal disturbances (diarrhea in 3.8% of patients). This sets a new, unparalleled benchmark for the safety and efficacy of non-hormonal menopause care.

Table 2

Comparative Efficacy, Mechanisms of Action, and Clinical Safety Profiles of Non-Hormonal Pharmacotherapies for Menopausal Vasomotor Symptoms

Non-Hormonal Agent	Primary Mechanism of Action	VMS Reduction Efficacy	Key Benefits & Clinical Safety Profile
Fezolinetant (45 mg)	Selective NK3 Receptor Antagonist	50% - 65%	Direct hypothalamic target; mild transient headaches; requires liver enzyme monitoring.
Elinzanetant (120 mg)	Dual NK1 / NK3 Receptor Antagonist	60% - 65%	Significant improvement in sleep architecture; zero hepatotoxicity signals in 52-week trials.
Paroxetine (7.5 mg)	SSRI (Serotonin Reuptake Inhibitor)	40% - 50%	Modest efficacy; strictly contraindicated with Tamoxifen use due to severe CYP2D6 inhibition.
Venlafaxine	SNRI (Serotonin-Norepinephrine)	40% - 55%	Viable alternative for oncology patients; may cause mild nausea or transient

			blood pressure elevations.
Gabapentin	Calcium Channel Modulator	45% - 50%	Effective for nocturnal VMS; highly limited by daytime somnolence and dizziness.

Pharmacogenomics and Artificial Intelligence in Precision Care

The deployment of both hormonal and non-hormonal therapeutics is increasingly being dictated by the rapidly expanding field of pharmacogenomics, which utilizes an individual's genetic polymorphism data to predict drug metabolism, optimize efficacy, and prevent severe toxicity.

CYP2D6 and ESR1 Polymorphisms

The *CYP2D6* hepatic enzyme system is responsible for the metabolism of roughly 25% of all prescribed medications, including SSRIs and the critical breast cancer drug tamoxifen. Tamoxifen is a prodrug that strictly requires conversion by *CYP2D6* into endoxifen, its active metabolite, which possesses 100 times greater affinity for the estrogen receptor. Approximately 7% to 10% of women possess genetic variants rendering them "poor metabolizers" of *CYP2D6*.[1] If a breast cancer patient on tamoxifen is prescribed paroxetine (a potent *CYP2D6* inhibitor) to treat her severe VMS, the enzyme is completely blocked, endoxifen levels plummet, and her risk of lethal cancer recurrence skyrockets. Precision pharmacology demands that such patients undergo genomic mapping and be universally routed to non-inhibiting alternatives like venlafaxine or the new NK3 antagonists. Similarly, genetic variations in the Estrogen Receptor 1 (*ESR1*) gene dictate a woman's symptomatic sensitivity to exogenous estrogen, allowing clinicians to fine-tune MHT micro-dosing to maximize cardiovascular benefits while minimizing side effects.

AI-Driven Predictive Algorithms

Simultaneously, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is fundamentally optimizing postmenopausal health surveillance. Advanced ensemble AI models now process massive arrays of multi-omics data, genomic markers, and high-resolution imaging (such as HR-pQCT) to generate highly dynamic, real-time risk profiles. These AI algorithms have vastly surpassed conventional, static tools like the FRAX score for osteoporosis prediction, recognizing subtle micro-architectural bone deterioration long before fractures occur. By clustering these vast datasets, AI enables clinicians to identify the exact, optimal "window of opportunity" for initiating preventative therapies tailored to the specific biological aging trajectory of the individual patient.

Regenerative Medicine: MSC Exosomes and Autophagy Modulators

Despite optimal pharmacological management, traditional therapies fail to address the fundamental biological deficit underlying POI: the absolute depletion of the ovarian primordial follicle reserve. Regenerative medicine represents the ultimate frontier, offering true disease-modifying potential through the application of mesenchymal stem cells (MSCs) and natural molecular autophagy modulators.

Hypoxic MSC-Derived Exosomes and the SIRT3/PGC-1α Pathway

MSCs derived from human umbilical cords, bone marrow, and adipose tissue have demonstrated remarkable capabilities in rescuing ovarian function. Rather than differentiating directly into oocytes, MSCs exert their effects via powerful paracrine signaling, secreting growth factors (VEGF, IGF-1) that promote neo-angiogenesis and actively suppress apoptosis in surrounding granulosa cells.

The most significant breakthrough of 2025 involves the use of nanoscale exosomes derived from MSCs cultured under hypoxic conditions. Hypoxic preconditioning fundamentally alters the cargo of these extracellular vesicles, enriching them with highly protective microRNAs and proteins. When injected locally into the failing ovary, these exosomes rapidly penetrate the tissue and directly target mitochondrial dysfunction via the activation of the **SIRT3/PGC-1α pathway** [1],,. PGC-1α is a master regulator of mitochondrial biogenesis, and its downstream target, SIRT3 (a mitochondrial deacetylase), induces powerful reactive oxygen species (ROS)-detoxifying enzymes such as superoxide dismutase 2. Preclinical and early phase clinical trials (e.g., VL-POI-01) demonstrate that by completely rectifying mitochondrial oxidative stress, these hypoxic exosomes can restore AMH levels by 30% to 40%, rescue up to 75% of the dormant primordial follicle pool, and achieve clinical pregnancy rates of 10% to 15% in previously infertile POI cohorts.

Natural Autophagy Modulators

Acting synergistically with cellular therapies are natural, low-molecular-weight compounds capable of modulating cellular autophagy to clear damaged organelles and prevent premature follicle hyperactivation.

- **Resveratrol:** A potent polyphenol that directly activates SIRT1 and the AMP-activated protein kinase (AMPK) pathway. It enhances follicular autophagy, clears toxic ROS, and has been shown to increase residual AMH levels by up to 25% in POI models.
- **Quercetin:** Functions through the targeted inhibition of the mechanistic target of rapamycin (mTOR) pathway. By suppressing mTOR, quercetin prevents the premature mass-activation of dormant follicles, preserving the ovarian reserve.
- **Curcumin:** Balances the complex AMPK/mTOR axis, exerting profound anti-inflammatory effects within the ovarian microenvironment and upregulating critical antioxidant enzymes like glutathione peroxidase.

These compounds, combined with AI-guided monitoring and exosome delivery, represent the multi-targeted future of preserving reproductive longevity and mitigating pathological menopause at the cellular level.

Computational Implementation: Precision Stratification Algorithm

To translate these complex clinical guidelines into actionable clinical pathways, the following Python script utilizes the matplotlib and networkx libraries to generate a comprehensive, visual decision-tree algorithm. This computational model reflects the 2025/2026 ESE and ASRM precision pharmacological stratification guidelines for the management of pathological menopause.



The presented algorithm illustrates a precision-based pharmacological decision-making framework for the management of pathological menopause, including premature ovarian insufficiency (POI) and iatrogenic menopause occurring before the age of 45. The algorithm integrates diagnostic biomarkers, genomic risk profiling, and individualized therapeutic strategies in accordance with emerging clinical guidelines for personalized menopausal medicine. The decision process begins with the identification of patients presenting with clinical manifestations of pathological menopause. Diagnostic confirmation is established through endocrine biomarkers, primarily elevated follicle-stimulating hormone (FSH > 25 IU/L) and decreased anti-Müllerian hormone (AMH < 1.0 ng/mL), combined with standardized symptom evaluation using validated assessment tools such as the MQ6 symptom scale. This initial diagnostic stage ensures accurate differentiation between physiological menopausal transition and pathological ovarian insufficiency.

Following diagnostic confirmation, a comprehensive risk stratification step is implemented. This stage evaluates both cardiovascular and oncological risk factors, incorporating advanced genomic testing markers such as CYP2D6 and ESR1 polymorphisms. These genetic indicators may influence estrogen metabolism, hormone therapy response, and susceptibility to hormone-sensitive malignancies, thereby enabling a more individualized therapeutic approach.

Based on the integrated clinical and genomic risk profile, patients are categorized into two principal pathways: a high-risk pathway and a low-to-intermediate risk pathway. Patients classified within the high-risk group include those with estrogen receptor–positive breast cancer, a documented history of venous thromboembolism (VTE), or active hepatic disease. For this population, systemic menopausal hormone therapy (MHT) is considered contraindicated. Instead, non-hormonal pharmacological interventions are recommended, particularly neurokinin-3 receptor antagonists such as elinzanetant (120 mg) or fezolinetant (45 mg), which have demonstrated efficacy in the management of vasomotor symptoms. In cases where genitourinary syndrome of menopause (GSM) persists despite systemic therapy avoidance, localized treatment modalities are introduced. These include vaginal moisturizers, intravaginal dehydroepiandrosterone (DHEA), or ultra-low-dose topical estrogen preparations administered under careful clinical supervision.

Patients categorized as having low or intermediate risk follow a hormone-based therapeutic pathway. In these cases, menopausal hormone therapy is initiated and tailored according to the patient's specific reproductive aging category. Two principal subgroups are considered within this pathway. The first subgroup comprises patients diagnosed with premature ovarian insufficiency (age < 40 years). For these individuals, high-dose hormone replacement therapy is recommended to replicate physiological ovarian hormone levels and prevent long-term complications such as osteoporosis, cardiovascular disease, and cognitive decline. Typical regimens include 2

mg oral estradiol or 100 μg transdermal estradiol, with therapy maintained until the average age of natural menopause (approximately 51 years). The second subgroup includes women experiencing early menopause between 40 and 44 years of age. For this population, standard-dose precision hormone replacement therapy is recommended. Preferred regimens typically involve transdermal estradiol combined with micronized progesterone, which provides endometrial protection while minimizing thrombotic risk. Emerging therapeutic alternatives such as estetrol (E4)-based regimens may also be considered due to their selective tissue activity and potentially improved safety profile.

Conclusion

The therapeutic management of pathological menopause has definitively transcended the era of generalized, empirical treatment, evolving into a highly complex, precision-medicine discipline. The profound physiological disruptions precipitated by premature ovarian insufficiency and iatrogenic estrogen ablation demand rapid, biomarker-guided, and sustained clinical interventions. Based on the robust synthesis of 2024–2026 clinical guidelines, the initiation of Menopausal Hormone Therapy (MHT) remains the unequivocal gold standard for the prevention of cardiovascular disease, severe osteoporosis, and cognitive decline in women within the low-to-intermediate risk tiers. The contemporary optimization of these regimens—specifically the utilization of transdermal 17β-estradiol combined with metabolically neutral micronized progesterone, alongside the promising integration of the tissue-selective fetal estrogen Estetrol (E4)—maximizes therapeutic efficacy while virtually neutralizing the thromboembolic and oncological risks that historically plagued hormone therapy.

Concurrently, for the highly vulnerable cohorts facing iatrogenic menopause secondary to hormone-dependent malignancies, the pharmacological landscape has been radically transformed by the advent of dual NK1/NK3 receptor antagonists. Agents such as elinzanetant offer an unprecedented, highly effective non-hormonal lifeline, mitigating severe vasomotor symptoms and restoring sleep architecture without engaging systemic estrogenic pathways. Furthermore, the mandatory integration of pharmacogenomic profiling (such as CYP2D6 testing for tamoxifen users) and AI-driven predictive modeling ensures that every therapeutic decision is intricately tailored to the patient's unique genetic and metabolic blueprint.

Looking to the imminent future, regenerative medicine modalities—spearheaded by hypoxic MSC-derived exosomes targeting the SIRT3/PGC-1α mitochondrial rescue pathways—promise to shift the paradigm from mere symptomatic management to actual disease modification and fertility restoration. By aggressively dismantling global health equity barriers, actively diversifying clinical research, and adhering to these sophisticated, algorithm-driven stratification protocols, the global medical community is now equipped to fundamentally restore the long-term health span, vitality, and quality of life for millions of women navigating the profound challenges of pathological menopause.

References:

1. Aggarwal, N., et al. (2022). Menopause management: A manual for primary care. *Taiwanese Journal of Obstetrics and Gynecology, 61*(5), 949–952.

2. Al Wattar, B. H. (2024). 10 Non-oestrogen-based and complementary therapies for menopause. *Best Practice & Research Clinical Obstetrics & Gynaecology, 92*, 102421.

3. Albertazzi, P. (2006). A review of non-hormonal options for the relief of menopausal symptoms. *Treatments in Endocrinology, 5*(2), 101–113.

4. Ambikairajah, A., et al. (2022). A review of menopause nomenclature. *Reproductive Health, 19*(1), 1336.

5. American Society for Reproductive Medicine (ASRM). (2024). Evidence-based guideline: Premature ovarian insufficiency. *Fertility and Sterility*.

6. Appiah, D., Nwabuo, C. C., Ebong, I. A., Wellons, M. F., & Winters, S. J. (2021). Trends in age at natural menopause and reproductive life span among US women, 1959-2018. *JAMA, 325*(13), 1328-1330.

7. Baber, R. J., Panay, N., & Fenton, A. (2016). 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric, 19*, 109–150.

8. Bani-Irshaid, I. (2011). Histological findings in women with postmenopausal bleeding: Jordanian figures. *Eastern Mediterranean Health Journal, 17*(7), 582–586.

9. Bani-Irshaid, I. (2022). Various endometrial patterns and abnormalities in women with postmenopausal bleeding. *International Journal of Health Sciences, 6*(S6), 12883.

10. Barrett-Connor, E. (2001). Hormone replacement therapy (HRT)—risks and benefits. *International Journal of Epidemiology, 30*(3), 423–426.

11. Bidet, M., Bachelot, A., Bissauge, E., et al. (2011). Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. *J Clin Endocrinol Metab, 96*(12), 3864-3872.

12. Brown, A. M. C. (2020). Role of ovarian hormones in the modulation of sleep in females across the adult lifespan. *Endocrinology, 161*(9), bqaa128.

13. Burgos, N., Cintron, D., Latortue-Albino, P., et al. (2017). Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. *Endocrine, 58*, 413-425.

14. Camacho, P. M., Petak, S. M., Binkley, N., et al. (2020). American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. *Endocrine Practice, 26*, 1-46.

15. Cambray, S., Dubreuil, S., Tejedor, I., et al. (2023). Family building after diagnosis of premature ovarian insufficiency: a cross-sectional survey. *European Journal of Endocrinology, 188*(3).

16. Cameron-Pimblett, A., Davies, M. C., Burt, E., et al. (2019). Effects of Estrogen Therapies on Outcomes in Turner Syndrome. *The Journal of Clinical Endocrinology and Metabolism, 104*, 2820-2826.

17. Capel-Alcaraz, A. M. (2023). The efficacy of strength exercises for reducing the symptoms of menopause: A systematic review. *Journal of Clinical Medicine, 12*(2), 548.

18. Carroll, D. G. (2006). Nonhormonal therapies for hot flashes in menopause. *American Family Physician, 73*(3), 457–464.

19. Cartwright, B., Robinson, J., Seed, P. T., et al. (2016). Hormone Replacement Therapy Versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial. *J Clin Endocrinol Metab, 101*(9), 3497-3505.

20. Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. *JAMA, 324*(4), 369–380.

21. Cho, L., et al. (2023). Rethinking menopausal hormone therapy: For whom, what, when, and how long? *Circulation, 147*(6), 487–497.

22. Coelingh Bennink, H. J. T., Gosden, R., Stanczyk, F. Z., & Adashi, E. Y. (2025). The rediscovery of estetrol and its implications for estrogen treatment. *Menopause, 32*(7), 648-651.

23. Comparetto, C. (2023). Treatments and management of menopausal symptoms: Current status and future challenges. *OBM Geriatrics, 7*(3), 248.

24. Costa-Paiva, L., O Wender, M. C., Machado, R. B., et al. (2022). Effects of ultra-low dose hormone therapy on biochemical bone turnover markers in postmenopausal women. *Post Reproductive Health, 28*, 149–157.

25. Davis, S. R. (2023). Menopause—Biology, consequences, supportive care, and therapeutic options. *Cell, 186*(19), 4007–4024.

26. de Almeida, A. M., et al. (2025). Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: A systematic review and meta-analysis. *Obstetrics & Gynecology, 145*(3), 253–261.

27. De Medeiros, S. F. (2013). Abnormal bleeding during menopause hormone therapy: Insights for clinical management. *Clinical Medicine Insights: Women's Health, 6*, S10483.

28. Delanerolle, G., Phiri, P., Elneil, S., et al. (2025). Menopause: a global health and wellbeing issue that needs urgent attention. *The Lancet Global Health, 13*(2), e196-e198.

29. Dubrovina, S. O. (2025). Managing menopause after cancer: the problem and the solution. *Guidelines for the Practitioner, 1*(1), 134-144.

30. Ebrahimi, M. (2011). Pathogenesis and causes of premature ovarian failure: An update. *International Journal of Fertility & Sterility, 5*(2), 54–65.

31. Eger, R. R., et al. (2026). Expanding nonhormonal options for menopausal vasomotor symptoms: Clinical impact of elinzanetant. *Journal of Obstetrics and Gynaecology Research*.

32. ESHRE Guideline Group on POI. (2024). ESHRE clinical practice guideline on the management of premature ovarian insufficiency. *European Society of Human Reproduction and Embryology*.

33. European Society of Endocrinology (ESE). (2025). Clinical Practice Guideline for Management and Evaluation of Menopause and the Perimenopause. *European Journal of Endocrinology, 193*(4).

34. Faubion, S. S. (2023). New recommendations for nonhormonal therapies for menopause symptoms. *US Pharmacist*.

35. Ganderton, C. (2016). Does menopausal hormone therapy (MHT), exercise or a combination of both, improve pain? *BMC Women's Health, 16*, 311.

36. Gibson, D. A. (2020). Androgens, oestrogens and endometrium: A fine balance between perfection and pathology. *Journal of Endocrinology, 245*(3), 106.

37. Golezar, S., Ramezani Tehrani, F., Khazaei, S., Ebadi, A., & Keshavarz, Z. (2019). The global

prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. *Climacteric, 22*, 403–11.

38. Guo, Z.-Q. (2025). Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management. *Frontiers in Reproductive Health, 7*, 1694240.

39. Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10. *Menopause, 19*(4), 387–395.

40. Harper-Harrison, G. (2024). Hormone replacement therapy. *StatPearls*.

41. Hickey, M., et al. (2017). Non-hormonal treatments for menopausal symptoms. *BMJ, 359*, j5101.

42. Hillman, S., Mann, C., & Eccles, A. (2025). The MenopauseGAP study: Exploring inequalities in menopause care shaped by ethnicity, socioeconomic status and cultural norms. *British Journal of General Practice*.

43. Hoang, V. T. (2022). Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction. *Frontiers in Cell and Developmental Biology, 10*, 927274.

44. Houeis, L., et al. (2025). Premature ovarian insufficiency and diminished ovarian reserve: From diagnosis to current management and treatment. *Journal of Clinical Medicine, 14*(21), 7473.

45. Huang, Y., et al. (2025). The risk factors, pathogenesis and treatment of premature ovarian insufficiency. *Journal of Ovarian Research, 18*(1), 134.

46. Ishizuka, B. (2021). Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). *Frontiers in Endocrinology, 12*, 626924.

47. Jett, S. (2022). Endogenous and exogenous estrogen exposures: How women's reproductive health can drive brain aging. *Frontiers in Aging Neuroscience, 14*, 831807.

48. Johansson, T. (2024). Contemporary menopausal hormone therapy and risk of cardiovascular disease. *BMJ, 387*, e078784.

49. Ju, W., et al. (2025). Targeting programmed cell death with natural products: A potential therapeutic strategy for diminished ovarian reserve. *Frontiers in Pharmacology, 16*, 1623990.

50. Karkia, R. (2025). The association between metabolic syndrome and the risk of endometrial cancer. *Journal of Clinical Medicine, 14*(3), 751.

51. Labrie, F., Archer, D. F., Koltun, W., et al. (2018). Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness. *Menopause, 25*(11), 1339-1353.

52. Lee, S. R. (2020). The 2020 menopausal hormone therapy guidelines. *Journal of Menopausal Medicine, 26*(2), 69–98.

53. Makary, M. A. (2026). Updated labeling for menopausal hormone therapy. *JAMA, 335*(15), 1321.

54. Manson, J. E., et al. (2024). The Women's Health Initiative randomized trials and clinical practice: A review. *JAMA, 331*(20), 1748–1760.

55. McGlacken-Byrne, S. M., et al. (2022). Premature ovarian insufficiency. *Best Practice & Research Clinical Obstetrics & Gynaecology, 81*, 98–110.

56. Moyer, A. M., Miller, V. M., & Faubion, S. S. (2016). Could personalized management of menopause based on genomics become a reality? *Pharmacogenomics, 17*(7), 659–662.

57. Panay, N., et al. (2025). Elinzanetant for the treatment of vasomotor symptoms associated with menopause: A phase 3 randomized clinical trial. *JAMA Internal Medicine, 185*(11), 1319–1327.

58. Santoro, N. (2025). Novel nonhormonal treatments for vasomotor symptoms of menopause. *Current Opinion in Obstetrics and Gynecology, 37*(4), 193–197.

59. Simon, J. A., Goldstein, I., Kim, N. N., et al. (2018). The role of androgens in the treatment of genitourinary syndrome of menopause (GSM). *Menopause, 25*(7), 837-847.

60. Utian, W., Taziaux, M., Black, A., et al. (2024). The Effect of Estetrol (E4) on Patient-Reported Outcome Measures in Postmenopausal Women - Results From a Phase 3 Trial. *Journal of Neurosurgical Anesthesiology, 36*(1), 1302.

61. Vargas-Hernandez, V. M., et al. (2025). Artificial Intelligence in Menopause Management. *Mathews J Gynecol Obstet, 9*(1), 45.

62. Wang, P. H. (2025). Review article menopause part I: Vasomotor symptoms (I). *Taiwanese Journal of Obstetrics and Gynecology, 64*(1), 19–24.

63. Wang, R., et al. (2025). Precision medicine in premature ovarian insufficiency: A focus on the precision therapeutic strategies for mesenchymal stem cells. *Frontiers in Reproductive Health, 7*, 1694240.

64. Yang, X., et al. (2025). Non-hormone replacement therapy to overcome premature ovarian insufficiency: Advances in natural products and stem cells targeting autophagy. *Frontiers in Endocrinology, 16*, 1571021.

65. Zhang, S., et al. (2025). Exosomes derived from hypoxic mesenchymal stem cell ameliorate

premature ovarian insufficiency by reducing mitochondrial oxidative stress. *Scientific Reports, 15*, 90879.